SABSW
MaterialsSAB Biotherapeutics Inc - Warrants (25/07/2027)
$0.03+0.01 (+48.52%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SABSW Today?
No stock-specific AI insight has been generated for SABSW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.02$0.06
$0.03
Fundamentals
Market Cap—
P/E Ratio0.1
EPS$0.29
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin—
Debt / Equity—
Trading
Volume60K
Avg Volume (10D)—
Shares Outstanding—
SABSW News
17 articles- SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETYahoo Finance·May 5, 2026
- Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142Yahoo Finance·Apr 29, 2026
- SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026Yahoo Finance·Apr 22, 2026
- SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressYahoo Finance·Apr 15, 2026
- SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Mar 19, 2026
- SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Mar 18, 2026
- SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Mar 17, 2026
- SAB BIO Reports Third Quarter Financial Results and Recent Business HighlightsYahoo Finance·Nov 13, 2025
- SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142Yahoo Finance·Nov 4, 2025
- SAB BIO to Participate in Upcoming Investor ConferencesYahoo Finance·Nov 4, 2025
- SAB BIO Highlights Data in Multiple Presentations at EASDYahoo Finance·Sep 19, 2025
- SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of DiabetesYahoo Finance·Sep 3, 2025
- SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseYahoo Finance·Aug 7, 2025
- SAB BIO Reports Second Quarter Financial Results and Highlights Company UpdatesYahoo Finance·Aug 7, 2025
- SAB Biotherapeutics Raises $175 Million in Oversubscribed Private Placement; Shares Rise Pre-BellYahoo Finance·Jul 21, 2025
- SAB BIO Announces Oversubscribed $175 Million Private PlacementYahoo Finance·Jul 21, 2025
- SAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesYahoo Finance·May 9, 2025
All 17 articles loaded
Price Data
Open$0.00
Previous Close$0.02
Day High$0.00
Day Low$0.00
52 Week High$0.06
52 Week Low$0.02
52-Week Range
$0.02$0.06
$0.03
Fundamentals
Market Cap—
P/E Ratio0.1
EPS$0.29
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin—
Debt / Equity—
Trading
Volume60K
Avg Volume (10D)—
Shares Outstanding—
About SAB Biotherapeutics Inc - Warrants (25/07/2027)
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—